LivaNova Competitors

Varian Medical Systems (NYSE:VAR) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Varian Medical Systems and LivaNova's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Varian Medical Systems and LivaNova, as reported by MarketBeat.

Varian Medical Systems currently has a consensus price target of $177.70, indicating a potential upside of 0.36%. LivaNova has a consensus price target of $87.75, indicating a potential upside of 4.96%. Given LivaNova's stronger consensus rating and higher probable upside, analysts plainly believe LivaNova is more favorable than Varian Medical Systems.

Insider and Institutional Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 0.8% of Varian Medical Systems shares are held by insiders. Comparatively, 0.5% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Varian Medical Systems and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

Varian Medical Systems has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Varian Medical Systems has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Summary

Varian Medical Systems beats LivaNova on 10 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Masimo and LivaNova's gross revenue, earnings per share and valuation.

Masimo has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

81.6% of Masimo shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 11.5% of Masimo shares are held by insiders. Comparatively, 0.5% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Masimo and LivaNova's net margins, return on equity and return on assets.

Risk and Volatility

Masimo has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Masimo and LivaNova, as provided by MarketBeat.

Masimo currently has a consensus price target of $291.50, suggesting a potential upside of 33.97%. LivaNova has a consensus price target of $87.75, suggesting a potential upside of 4.96%. Given Masimo's stronger consensus rating and higher probable upside, analysts plainly believe Masimo is more favorable than LivaNova.

Summary

Masimo beats LivaNova on 12 of the 14 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Profitability

This table compares LivaNova and CONMED's net margins, return on equity and return on assets.

Risk and Volatility

LivaNova has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Insider & Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by insiders. Comparatively, 5.4% of CONMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for LivaNova and CONMED, as reported by MarketBeat.com.

LivaNova presently has a consensus price target of $87.75, suggesting a potential upside of 4.96%. CONMED has a consensus price target of $117.3333, suggesting a potential downside of 16.09%. Given LivaNova's higher probable upside, analysts clearly believe LivaNova is more favorable than CONMED.

Earnings and Valuation

This table compares LivaNova and CONMED's gross revenue, earnings per share (EPS) and valuation.

CONMED has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats LivaNova on 8 of the 13 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares LivaNova and InMode's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares LivaNova and InMode's top-line revenue, earnings per share and valuation.

InMode has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Insider & Institutional Ownership

89.1% of LivaNova shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for LivaNova and InMode, as reported by MarketBeat.com.

LivaNova currently has a consensus price target of $87.75, suggesting a potential upside of 4.96%. InMode has a consensus price target of $80.25, suggesting a potential upside of 15.48%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than LivaNova.

Summary

InMode beats LivaNova on 10 of the 14 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Outset Medical (NASDAQ:OM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares LivaNova and Outset Medical's gross revenue, earnings per share and valuation.

Outset Medical has lower revenue, but higher earnings than LivaNova.

Profitability

This table compares LivaNova and Outset Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for LivaNova and Outset Medical, as provided by MarketBeat.

LivaNova currently has a consensus target price of $87.75, suggesting a potential upside of 4.96%. Outset Medical has a consensus target price of $58.20, suggesting a potential upside of 33.61%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than LivaNova.

Insider and Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. Comparatively, 84.6% of Outset Medical shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

LivaNova beats Outset Medical on 5 of the 9 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Comparatively, 0.5% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

BioLife Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Valuation & Earnings

This table compares BioLife Solutions and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

BioLife Solutions has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioLife Solutions and LivaNova, as provided by MarketBeat.

BioLife Solutions currently has a consensus price target of $46.6667, suggesting a potential upside of 58.25%. LivaNova has a consensus price target of $87.75, suggesting a potential upside of 4.96%. Given BioLife Solutions' stronger consensus rating and higher probable upside, equities research analysts plainly believe BioLife Solutions is more favorable than LivaNova.

Profitability

This table compares BioLife Solutions and LivaNova's net margins, return on equity and return on assets.

Summary

BioLife Solutions beats LivaNova on 8 of the 14 factors compared between the two stocks.